Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
VolitionRX ( (VNRX) ) has provided an announcement.
On December 5, 2025, Volition Veterinary Diagnostics Development, a subsidiary of VolitionRx Limited, announced the termination of its employment agreement with CEO Dr. Salvatore Thomas Butera, effective January 31, 2026. This decision is part of the company’s cost-realignment efforts, leading to the elimination of the CEO position and redistribution of duties within the company. Dr. Butera is expected to continue with the company on a part-time consulting basis after the termination.
The most recent analyst rating on (VNRX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
VolitionRX’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis also indicates bearish momentum, further weighing down the score. While the earnings call provided some positive insights into strategic partnerships and revenue growth, these factors are not enough to offset the significant financial and technical challenges.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited operates in the veterinary diagnostics industry, focusing on developing innovative diagnostic products for animal health through its subsidiary, Volition Veterinary Diagnostics Development, LLC.
Average Trading Volume: 1,343,105
Technical Sentiment Signal: Sell
Current Market Cap: $37.12M
For an in-depth examination of VNRX stock, go to TipRanks’ Overview page.